Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

The list of currently pending claims is presented below.

1. (Currently amended) A method of modulating an Edg-3 receptor mediated biological activity comprising contacting a cell expressing the Edg-3 receptor with an amount of ~~an~~ a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity wherein the modulator is a compound of ~~the structural formula~~ Formula (I):



(I)

or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein~~;~~

each ~~of~~ R_1, R_2 and R_3 is a member independently selected from the group consisting of -H, -halo, $-NO_2$, -CN, $-C(R_5)_3$, $-(CH_2)_mOH$, $-N(R_5)(R_5)$, $-O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, -phenyl, $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, $-(C_5-C_{10})$heteroaryl, -naphthyl, $-(C_3-C_{10})$heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$, $-NHC(O)NHR_5$, ~~-heterocylcoalkyl~~ heterocycloalkyl, $-C(S)N(R_5)(R_5)$, $-(C_1-C_{10})$alkylNHC(O)$(CH_2)_mR_5$, $-(C_1-C_{10})$alkylNR_5R_5 $-OC(O)(CH_2)$mCHR_5R_5, $-CO_2(CH_2)_mCHR_5R_5$, $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, ~~or~~ and



~~R_3 is H, $C(R_5)_3$, $(CH_2)_mOH$, $C(O)R_5$, $C(O)NR_5R_5$, $C(O)NH(CH_2)m(R_5)$, benzyl, $CO_2CH(R_5)(R_5)$, $(C_1$-$C_{10})$alkyl, $(C_2$-$C_{10})$alkenyl, $(C_2$-$C_{10})$alkynyl, $(C_3$-$C_{10})$cycloalkyl, $(C_8$-$C_{14})$bicycloalkyl, $(C_5$-$C_{10})$cycloalkenyl, (C_5)heteroaryl, (C_6)heteroaryl, $(C_5$-$C_{10})$heteroaryl, naphthyl, $(C_3$-$C_{10})$heterocycle, $CO_2(CH_2)_mR_5$, N(OH)aryl, $NHC(O)R_5$, $NHC(O)OR_5$, $NHC(O)NHR_5$, N=C(aryl), heterocycleoalkyl, $(C_1$-$C_{10})$alkyl$NHC(O)(CH_2)_mR_5$, $(C_1$-$C_{10})$alkylNR_5R_5, $OC(O)(CH_2)_mCHR_5R_5$, $CO_2(CH_2)_mCHR_5R_5$, $OC(O)OR_5$, SR_5, $S(O)R_5$, $S(O)_2R_5$, $S(O)_2NHR_5$, or~~



wherein~~;~~

each R_5 and R_6 is a member independently selected from group consisting of -H, -halo, $-NO_2$, -CN, -OH, $-CO_2H$, $-N(C_1$-$C_{10})$alkyl$(C_1$-$C_{10})$alkyl, $-O(C_1$-$C_{10})$alkyl, $-C(O)(C_1$-$C_{10})$alkyl, $-C(O)NH(CH_2)_m(C_1$-$C_{10})$alkyl, $-OCF_3$, -benzyl, $-CO_2(CH_2)_mCH((C_1$-$C_{10})$alkyl$(C_1$-$C_{10})$alkyl), $-CO_2(C_1$-$C_{10})$alkyl, $-(C_1$-$C_{10})$alkyl, $-(C_2$-$C_{10})$alkenyl, $-(C_2$-$C_{10})$alkynyl, $-(C_3$-$C_{10})$cycloalkyl, $-(C_8$-$C_{14})$bicycloalkyl, $-(C_5$-$C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, -phenyl, naphthyl, $-(C_3$-$C_{10})$heterocycle, $-CO_2(CH_2)_m(C_1$-$C_{10})$alkyl, $-CO_2(CH_2)_mH$, $-NHC(O)(C_1$-$C_{10})$alkyl, $-NHC(O)NH(C_1$-$C_{10})$alkyl, -NH(aryl), -N=C(aryl), $-OC(O)O(C_1$-$C_{10})$alkyl, ~~or~~ and $-SO_2NH_2$;

X is selected from O, S, ~~or~~ and $N(R_5)$;

R_1, R_2 or R_3 taken in combination can form one or more substituted or unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered aromatic ring;

two R_6 groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or heterocyclic ring or a 6-membered aromatic ring;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

2. (Currently amended) A method of modulating an ~~Edg-2~~ Edg-3 receptor mediated biological activity in a subject comprising administering to the subject a therapeutically effective amount of a modulator of the ~~Edg-2~~ Edg-3 receptor wherein the modulator is a compound of ~~the structural formula~~ Formula (II):



(II)

or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein;

each ~~of~~ R_1, R_2, R_3, R_4, R_7 and R_8 is a member independently selected from the group consisting of -H, -halo, $-NO_2$, -CN, $-C(R_5)_3$, $-(CH_2)_mOH$, $-N(R_5)(R_5)$, $-O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, $-CO_2CH(R_5)(R_5)$, $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, $-(C_5\text{-}C_{10})$heteroaryl, -naphthyl, $-(C_3\text{-}C_{10})$heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$, $-NHC(O)NHR_5$, ~~-heterocyleoalkyl-~~ -heterocycloalkyl, $-C(S)N(R_5)(R_5)$, $-(C_1\text{-}C_{10})$alkylNHC(O)$(CH_2)_mR_5$, $-(C_1\text{-}C_{10})$alkylNR_5R_5, $-OC(O)(CH_2)mCHR_5R_5$, $-CO_2(CH_2)_mCHR_5R_5$, $OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, ~~or~~ and



~~R_3 is -H $-C(R_5)_3$, $-(CH_2)_mOH$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, -benzyl, $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_9-C_{14})$bicycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, $-(C_5-C_{10})$heteroaryl, naphthyl, $-(C_3-C_{10})$heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$, $-NHC(O)NHR_5$, -N=C(aryl), -heterocycloalkyl, $-(C_1-C_{10})$alkylNHC(O)$(CH_2)_mR_5$, $-(C_1-C_{10})$alkylNR_5R_5, $-OC(O)(CH_2)_mCHR_5R_5$, $-CO_2(CH_2).CHR_5R_5$, $-OC(O)OR_5$ $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, or~~



wherein~~;~~

each R_5 and R_6 is a member independently selected from the group consisting of -H, -halo, $-NO_2$, -CN, -OH, $-CO_2H$, $-N(C_1-C_{10})$alkyl(C_1-C_{10})alkyl, $-O(C_1-C_{10})$alkyl, $-C(O)(C_1-C_{10})$alkyl, $-C(O)NH(CH_2)_m(C_1-C_{10})$alkyl, $-OCF_3$, -benzyl, $-CO_2(CH_2)_mCH((C_1.C_{10})$alkyl$(C_1.C_{10})$alkyl), $-CO_2(C_1-C_{10})$alkyl, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, -phenyl, naphthyl, $-(C_3-C_{10})$heterocycle, $-CO_2(CH_2)_m(C_1-C_{10})$alkyl, $-CO_2(CH_2)_mH$, $-NHC(O)(C_1-C_{10})$alkyl, $-NHC(O)NH(C_1-C_{10})$alkyl, -NH(aryl), -N=C(aryl), $-OC(O)O(C_1-C_{10})$alkyl, ~~or~~ and $-SO_2NH_2$;

X is selected from O, S, ~~or~~ and $N(R_5)$;

R_1, and R_2, R_2 and R_3, R_3 and R_4, R_4 and R_7, or R_7 and R_8 taken in combination can form one or more substituted or unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered aromatic ring;

two R_6 groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or heterocyclic ring or a 6-membered aromatic ring;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

3. (Original) The method of Claim **1** or **2**, wherein the modulator is an agonist.

4. (Original) The method of Claim **1** or **2**, wherein the modulator is an antagonist.

5. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

6. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 40 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

7. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 12 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

8. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

9. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 20 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

10. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

11. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 40 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7

receptors.

12. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 12 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

13. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

14. (Original) The method of Claim **1** or **2**, wherein the biological activity is cell proliferation.

15. (Currently amended) The method of Claim **14**, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

16. (Currently amended) The method of Claim **14**, wherein the modulator exhibits at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

17. (Currently amended) The method of Claim **14**, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

18. (Currently amended) The method of Claim **14**, wherein the modulator exhibits at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

19. (Currently amended) The method of Claim **14**, wherein cell proliferation leads to cancer selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer ~~or~~ and ~~prostrate~~ prostate cancer.

20. (Original) The method of Claim **14**, wherein cell proliferation is stimulated by LPA.

21. (Currently amended) The method of Claim **1** or **2**, wherein the biological activity is selected from the group consisting of calcium mobilization, VEGF synthesis, IL-8 synthesis,

platelet activation, cell migration, phosphoinositide hydrolysis, inhibition of cAMP formation, actin polymerization, apoptosis, angiogenesis, inhibition of wound healing, inflammation, cancer invasiveness, supressing autoimmune responses, ~~or~~ and atherogenesis.

22. (Currently amended) The method of Claim **1** or **2** wherein the modulator binds to the ~~Edg-2~~ Edg-3 receptor with a binding constant of at least about 10 ~~nm~~ nM.

23. (Currently amended) The method of Claim **1** or **2** wherein the modulator binds to the ~~Edg-2~~ Edg-3 receptor with a binding constant between about 100 fM and 1 μM. ~~and 100 fM.~~

24. (Original) The method of Claim **1** or **2**, wherein the modulator is a nucleic acid, protein or carbohydrate.

25. (Original) The method of Claim **1** or **2**, wherein the modulator is an organic molecule of molecular weight of less than 750 daltons.

26. (Currently amended) The method of Claim **1**, wherein the cell is selected from the group consisting of a hepatoma cell, an ovarian cell, an epithelial cell, a fibroblast cell, a neuronal cell, a carcinoma cell, a pheochromocytoma cell, a myoblast cell, a platelet cell ~~or~~ and a fibrosarcoma cell.

27. (Currently amended) The method of Claim **21**, wherein the cell is selected from the group consisting of OV202 human ovarian cell, a HTC rat hepatoma cell, a CAOV-3 human ovarian cancer cell, MDA-MB-453 breast cancer cell, MDA-MB-231 breast cancer cell, HUVEC cells A431 human epitheloid carcinoma cell ~~or~~ and a HT-1080 human fibrosarcoma cell.

28. (Currently amended) The method of Claim ~~25~~ 1 or 2 wherein the modulator has ~~the~~ a ~~following structural~~ formula selected from:



113



115



117

; and



119

29. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to ~~a~~ said patient ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I) or (II).

30. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial cancer; cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, ~~prostrate~~ prostate cancer, adult respiratory distress syndrome (ARDS), asthma, transcorneal freezing, cutaneous burns, ischemia ~~or~~ and ~~arthesclerosis~~ atherosclerosis in a patient in need of said treatment or said prevention, said method comprising administering to ~~a~~ said patient ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I)

or (II).

31. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to ~~a~~ said patient ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I) or (II) and one or more agonists or antagonists of an ~~Edg-2~~ Edg-3 receptor.

32. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to ~~a~~ said patient ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I) or (II) and one or more drugs useful in treating or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, or cardiovascular diseases.

33. (New) A method of treating cardiovascular disease in a patient comprising:

administering to the patient a therapeutically effective amount of a modulator of an Edg-3 receptor wherein the receptor is a compound of Formula (III):



(III)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

R_3 is independently a member selected from the group consisting of -H, -halo, -NO_2, -CN, -$C(R_5)_3$, -$(CH_2)_mOH$, -$N(R_5)(R_5)$, -$O(CH_2)_mR_5$, -$C(O)R_5$, -$C(O)NR_5R_5$, -$C(O)NH(CH_2)_m(R_5)$, -OCF_3, -benzyl,- -phenyl, -$CO_2CH(R_5)(R_5)$, -$(C_1$-$C_{10})$alkyl, -$(C_2$-$C_{10})$alkenyl, -$(C_2$-$C_{10})$alkynyl, -$(C_3$-$C_{10})$cycloalkyl, -$(C_8$-$C_{14})$bicycloalkyl, -$(C_5$-$C_{10})$cycloalkenyl, -(C_5)heteroaryl, -(C_6)heteroaryl, -$(C_5$-$C_{10})$heteroaryl, -naphthyl, -$(C_3$-$C_{10})$heterocycle, -$CO_2(CH_2)_mR_5$, -N(OH)aryl, -$NHC(O)R_5$, -$NHC(O)OR_5$, -$NHC(O)NHR_5$, -heterocycloalkyl, -$C(S)N(R_5)(R_5)$, -$(C_1$-$C_{10})$alkylNHC$(O)(CH_2)_mR_5$, -$(C_1$-$C_{10})$alkylNR_5R_5, -$OC(O)(CH_2)$mCHR_5R_5, -$CO_2(CH_2)_mCHR_5R_5$, $OC(O)OR_5$, -SR_5, -$S(O)R_5$, -$S(O)_2R_5$, -$S(O)_2NHR_5$, and



wherein

each R_5 and R_6 is a member independently selected from the group consisting of -H, -halo, -NO_2, -CN, -OH, -CO_2H, -N$(C_1$-$C_{10})$alkyl, $(C_1$-$C_{10})$alkyl, -O$(C_1$-$C_{10})$alkyl, -C$(O)(C_1$-$C_{10})$alkyl, -C$(O)NH(CH_2)_m(C_1$-$C_{10})$alkyl, -OCF_3, -benzyl, -phenyl, -$CO_2(CH_2)_mCH((C_1$-$C_{10})$alkyl$(C_1$-$C_{10})$alkyl), -$CO_2(C_1$-$C_{10})$alkyl, -$(C_1$-$C_{10})$alkyl, -$(C_2$-$C_{10})$alkenyl, -$(C_2$-$C_{10})$alkynyl, -$(C_3$-$C_{10})$cycloalkyl, -$(C_8$-$C_{14})$bicycloalkyl, -$(C_5$-$C_{10})$cycloalkenyl, -(C_5)heteroaryl, -(C_6)heteroaryl, -phenyl, naphthyl, -$(C_3$-$C_{10})$heterocycle, -$CO_2(CH_2)_m(C_1$-$C_{10})$alkyl, -$CO_2(CH_2)_mH$, -NHC$(O)(C_1$-$C_{10})$alkyl, -NHC$(O)NH(C_1$-$C_{10})$alkyl, -NH(aryl), -N=C(aryl), -OC$(O)O(C_1$-$C_{10})$alkyl, and -SO_2NH_2;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

34. (New) The method of claim **33**, wherein R_3 is a phenyl group.

35. (New) The method of claim **34**, wherein said phenyl group is substituted.

36. (New) The method of claim **35**, wherein said compound is



117

37. (New) The method of claim **33**, wherein said cardiovascular disease is selected from the group consisting of ischemia and atherosclerosis.

38. (New) A method of treating cardiovascular disease in a patient comprising:

administering to the patient a therapeutically effective amount of a modulator of an Edg-3 receptor wherein the receptor is a compound of Formula (IV):



(IV)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

each R_2 is a member independently selected from the group consisting of -H, -halo, $-NO_2$, -CN, $-C(R_5)_3$, $-(CH_2)_mOH$, $-N(R_5)(R_5)$, $-O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$,

-C(O)NH(CH_2)$_m$(R_5), -OCF_3, -benzyl, -$CO_2CH(R_5)(R_5)$, -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_5)heteroaryl, -(C_6)heteroaryl, -(C_5-C_{10})heteroaryl, -naphthyl, -(C_3-C_{10})heterocycle, -CO_2(CH_2)$_m$$R_5$, -N(OH)aryl, -NHC(O)$R_5$, -NHC(O)O$R_5$, -NHC(O)N$HR_5$, -heterocylcoalkyl, -C(S)N(R_5)(R_5), -(C_1-C_{10})alkylNHC(O)(CH_2)$_m$$R_5$, -($C_1$-$C_{10}$)alkylN$R_5R_5$, -OC(O)($CH_2$)mC$HR_5R_5$, -$CO_2$($CH_2$).C$HR_5R_5$, OC(O)O$R_5$, -$SR_5$, -S(O)$R_5$, -$S(O)_2R_5$, -$S(O)_2NHR_5$, and



wherein

each R_5 and R_6 is a member independently selected from the group consisting of -H, -halo, -NO_2, -CN, -OH, -CO_2H, -N(C_1-C_{10})alkyl, (C_1-C_{10})alkyl, -O(C_1-C_{10})alkyl, -C(O)(C_1-C_{10})alkyl, -C(O)NH(CH_2)m(C_1-C_{10})alkyl, -OCF_3, -benzyl, -CO_2(CH_2)$_m$CH((C_1-C_{10})alkyl(C_1-C_{10})alkyl), -CO_2(C_1-C_{10})alkyl, -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_5)heteroaryl, -(C_6)heteroaryl, -phenyl, naphthyl, -(C_3-C_{10})heterocycle, -CO_2(CH_2)$_m$(C_1-C_{10})alkyl, -CO_2(CH_2)$_m$H, -NHC(O)(C_1-C_{10})alkyl, -NHC(O)NH(C_1-C_{10})alkyl, -NH(aryl), -N=C(aryl), -OC(O)O(C_1-C_{10})alkyl, and -SO_2NH_2;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

39. (New) The method of claim **38**, wherein R_2 is -C(O)R_5.

40. (New) The method of claim **39**, wherein R_5 is a (C_1-C_{10})alkyl group.

41. (New) The method of claim **40**, wherein said (C_1-C_{10})alkyl is a methyl group.

42. (New) The method of claim **38**, wherein said cardiovascular disease is selected from the group consisting of ischemia and atherosclerosis.